CpG islands in MyD88 and ASC/PYCARD/TMS1 promoter regions are differentially methylated in head and neck squamous cell carcinoma and primary lung squamous cell carcinoma

Šutić, Maja; Baranašić, Jurica; Kovač Bilić, Lana; Bilić, Mario; Jakovčević, Antonija; Brčić, Luka; Seiwerth, Sven; Jakopović, Marko; Samaržija, Miroslav; Zechner, Ulrich; Knežević, Jelena (2021) CpG islands in MyD88 and ASC/PYCARD/TMS1 promoter regions are differentially methylated in head and neck squamous cell carcinoma and primary lung squamous cell carcinoma. Diagnostic pathology, 16 . ISSN 1746-1596

Preview

PDF - Published Version - article Available under License Creative Commons Attribution. Download (739kB) | Preview

Abstract

Background: Patients with head and neck squamous cell carcinoma (HNSCC) can develop lung squamous cell carcinoma (LuSCC), which could be the second primary tumor or HNSCC metastasis. Morphologically it is difficult to distinguish metastatic HNSCC from a second primary tumor which presents a significant diagnostic challenge. Differentiation of those two malignancies is important because the recommended treatments for metastatic HNSCC and primary LuSCC differ significantly. We investigated if the quantification of the promotor methylation status in HNSCC and LuSCC differs. Methods: Primary HNSCC (N = 36) and LuSCC (N = 17) were included in this study. Methylation status in the ASC/TMS1/PYCARD (apoptosis- associated speck-like protein containing a caspase recruitment domain ; 8 CpG sites) and MyD88 (Myeloid differentiation primary response protein 88 ; 10 CpG sites) promoters was analyzed. Bisulfite converted DNA, isolated from tumor tissue was quantified using pyrosequencing. Results of pyrosequencing analysis were expressed as a percentage for each tested CpG site. Receiver-operating characteristic (ROC) curve analysis was used for the evaluation of the diagnostic properties of selected biomarkers. Results: CpG sites located in the promoters of ASC/TMS1/PYCARD_CpG8 (- 65 upstream) and MyD88_CpG4 (- 278 upstream) are significantly hypermethylated in the HNSCC when compared with LuSCC (p ≤ 0.0001). By performing ROC curve analysis we showed that corresponding areas under the curve (AUC) were 85-95%, indicating that selected CpG sites are useful for a distinction between primary LuSCC and primary HNSCC. Conclusions: Results of the present study indicate that there is a significant difference in the methylation status of tested genes between primary HNSCC and LuSCC. However, to prove this approach as a useful tool for distinguishing second primary LuSCC from HNSCC metastasis, it would be necessary to include a larger number of samples, and most importantly, metastatic samples.

Item Type:	Article
Uncontrolled Keywords:	CpG ; diagnostic biomarker ; HNSCC ; lung ; methylation ; second primary tumor
Subjects:	BIOMEDICINE AND HEALTHCARE > Clinical Medical Sciences
Divisions:	Division of Molecular Medicine
Projects:	Project title Project leader Project code Project type Genetički i epigenetički biomarkeri urođene imunosti u KOPB-u i karcinomu pluća Knežević, Jelena IP-2016-06-1441 HRZZ
Depositing User:	Jelena Knežević
Date Deposited:	24 Jan 2022 09:07
URI:	http://fulir.irb.hr/id/eprint/6902
DOI:	10.1186/s13000-021-01078-3

Actions (login required)

View Item